IC Targets: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:IC Targets}} | ||
|name=IC Targets | {{Infobox company | ||
| | | name = IC Targets AS | ||
| | | org_number = 984531524 | ||
| | | founded = 2002-02-16 | ||
| | | employees = Not disclosed | ||
| | | address = Norway | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://www.ictargets.com | |||
| nht_category = Startup | |||
| description = IC Targets (Norwegian Contrasts) is a life science company dedicated to developing manganese-based MRI contrast agents and new methods to improve diagnostic imaging. The company focuses on manganese as an alternative to gadolinium-based contrast agents, addressing concerns about gadolinium deposition in tissues. | |||
| notes = Founded 2002 — older than most NHT members. Manganese MRI contrast is an active research area addressing gadolinium safety concerns. | |||
| related_companies = [[NordicImagingLab]], [[Hemispherian]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Diagnostics, Medical Imaging, Contrast Agents | |||
| sources = https://www.ictargets.com; https://data.brreg.no/enhetsregisteret/api/enheter/984531524 | |||
}} | }} | ||
== | == About == | ||
IC Targets AS (Norwegian Contrasts) is a Norwegian life science company developing novel MRI contrast agents based on manganese chemistry. Founded in 2002, making it one of the oldest companies in the NHT cluster. | |||
== | == Technology == | ||
The company's core innovation is manganese-based MRI contrast agents. Conventional MRI contrast agents are based on gadolinium, which has raised safety concerns due to deposition in brain tissues and kidneys. Manganese is a naturally occurring mineral (essential trace element) that can serve as an alternative MRI contrast agent, potentially offering improved safety profiles. | |||
[[Category: | == Market Need == | ||
[[Category: | |||
Gadolinium-based contrast agents are used in approximately 30-50% of MRI examinations globally. Growing concerns about gadolinium retention in the brain and other tissues have created interest in alternative contrast technologies. A manganese-based agent that maintains diagnostic efficacy while reducing safety concerns would address a significant market need. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Diagnostics]] | |||
[[Category:Medical Imaging]] | |||
[[Category:Contrast Agents]] | |||
Latest revision as of 20:14, 14 April 2026
About[edit]
IC Targets AS (Norwegian Contrasts) is a Norwegian life science company developing novel MRI contrast agents based on manganese chemistry. Founded in 2002, making it one of the oldest companies in the NHT cluster.
Technology[edit]
The company's core innovation is manganese-based MRI contrast agents. Conventional MRI contrast agents are based on gadolinium, which has raised safety concerns due to deposition in brain tissues and kidneys. Manganese is a naturally occurring mineral (essential trace element) that can serve as an alternative MRI contrast agent, potentially offering improved safety profiles.
Market Need[edit]
Gadolinium-based contrast agents are used in approximately 30-50% of MRI examinations globally. Growing concerns about gadolinium retention in the brain and other tissues have created interest in alternative contrast technologies. A manganese-based agent that maintains diagnostic efficacy while reducing safety concerns would address a significant market need.